Authors/Disclosures
|
Jerry R. Mendell, MD, FAAN
(The Research Institute at Nationwide Children's Hospital)
|
Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vertex. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Novartis. Dr. Mendell has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta Therapeutics . The institution of Dr. Mendell has received research support from Sarepta. |
|
Louise R. Rodino-Klapac
(Sarepta Therapeutics)
|
Ms. Rodino-Klapac has received personal compensation for serving as an employee of Sarepta Therapeutics, Inc.. Ms. Rodino-Klapac has received stock or an ownership interest from Sarepta Therapeutics. Ms. Rodino-Klapac has received intellectual property interests from a discovery or technology relating to health care. |
|
Zarife Sahenk, MD, PhD, FAAN
(The Research Institute at Nationwide Childrens.org)
|
Dr. Sahenk has nothing to disclose. |
|
Radu Tanasescu, MD, PhD, FAAN
(Clinical Neurology)
|
Dr. Tanasescu has received personal compensation for serving as an employee of Merck. Dr. Tanasescu has received personal compensation for serving as an employee of Novartis. Dr. Tanasescu has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Tanasescu has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Merck. Dr. Tanasescu has received research support from UK MRC grant MR/T024402/1. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Linda P. Lowes, PT PhD
|
The institution of Ms. Lowes has received research support from Sarepta Therapeutics. |
|
|
No disclosure on file |
|
|
No disclosure on file |
|
Sarah E. Lewis
(Sarepta Therapeutics)
|
Mrs. Lewis has received personal compensation for serving as an employee of Sarepta Therapeutics . Mrs. Lewis has stock in Sarepta Therapeutics. |
|
|
No disclosure on file |
|
Kevin M. Flanigan, MD, FAAN
(Nationwide CHildrens Hospital)
|
Dr. Flanigan has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sarepta. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Apic Bio. Dr. Flanigan has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for AavantiBio. Dr. Flanigan has stock in 4D Molecular Therapeutics. The institution of Dr. Flanigan has received research support from Abeona Therapeutics. The institution of Dr. Flanigan has received research support from Sarepta Therapeutics. The institution of Dr. Flanigan has received research support from Astellas Therapeutics. Dr. Flanigan has received intellectual property interests from a discovery or technology relating to health care. |
|
|
No disclosure on file |
|
Christopher Walker, PhD
(The Research Institute)
|
No disclosure on file |
|
|
No disclosure on file |
|
Hugh D. Allen
(Nationwide Childrens)
|
No disclosure on file |
|
Christopher Shilling, MS
(Nationwide Children'S Hospital)
|
No disclosure on file |
|
|
No disclosure on file |
|
Peter Sazani, PhD
|
No disclosure on file |
|
|
No disclosure on file |